Efficacy of Glycaemic Control of Biphasic Insulin Aspart (NovoMix 30 [insulin aspart/insulin protamine aspart]) or Insulin Detemir (Levemir) in Patients With Type 1 or 2 Diabetes Mellitus.

Trial Profile

Efficacy of Glycaemic Control of Biphasic Insulin Aspart (NovoMix 30 [insulin aspart/insulin protamine aspart]) or Insulin Detemir (Levemir) in Patients With Type 1 or 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Insulin aspart/insulin protamine aspart; Insulin detemir
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Oct 2008 Actual patient number (400) added as reported by ClinicalTrials.gov.
    • 08 Oct 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top